Long-term remission in a child with refractory EBV þ hydroa vacciniforme-like T-cell lymphoma through sequential matched EBV þ -related allogeneic hematopoietic SCT followed by donor-derived EBV-specific cytotoxic T-lymphocyte immunotherapy
1
HV-like lymphoma is a peripheral T-cell lymphoma manifested by dermal lesions in mostly sun-exposed areas. Lesions are papulovesicular with ulceration, crusting and edematous changes that leave residual scars. Patients have a backdrop of chronic active EBV infection that usually affects T lymphocytes. 2 Refractory to chemotherapy, HVlike lymphoma is a smoldering yet fatal disease. 3 Allogeneic hematopoietic SCT (allo-SCT) offers the only established curative option. 4 Recent developments in EBV-specific CTL immunotherapeutics may offer an exciting novel treatment approach for this high-risk group of patients. EBV-CTL immunotherapy has demonstrated efficacy in preventing the onset of type III latency EBV þ LPD when given as prophylaxis to 4100 allo-SCT recipients and has induced sustained CRs in 11 of 13 patients with EBV þ B-cell post-transplant LPD. 5 We report on an Ecuadorian male who presented at age 11 years with a 3-year history of recurrent papulovesicular rash on sun-exposed skin that would spontaneously heal leaving pitting scars. At the time of presentation, these lesions were persistent, widespread, and associated with systemic symptoms. Skin biopsy revealed spongiosis, necrosis and a deep atypical CD3
PCR analysis demonstrated monoclonal TCR-g gene rearrangement in the skin biopsy, peripheral blood and BM. EBV PCR and serology testing were strongly positive while liver enzyme and lactate dehydrogenase levels were elevated. Computed tomography scan was originally normal; however, positron emission tomography (PET) scan revealed cervical adenopathy. BM and cerebrospinal fluid studies did not show overt morphologic evidence of disease. On the basis of these findings, a diagnosis of systemic EBV þ HV-like T-cell lymphoma was established.
His disease was refractory to multiple chemotherapy regimens. It persisted despite receiving two cycles of CHOEP (CY, doxorubicin, VCR, etoposide, prednisone), followed by four cycles of hyper-CVAD (CY, VCR, doxorubicin, dexamethasone), followed by high-dose MTX. The skin lesions regressed transiently with each regimen; however, they invariably recurred and the EBV PCR and TCR rearrangement studies remained persistently positive. Refractory to chemotherapy, the patient went on to receive reduced-intensity conditioning followed by allo-SCT from a 5/6 HLA-matched related donor who was EBV þ by serology. Pre-allo-SCT evaluation found the patient with active disease-persistent skin lesions with positive EBV PCR and TCR rearrangement studies. The patient underwent conditioning with the reduced-intensity regimen reported by Corradini et al. 6 combining thiotepa, CY and fludarabine for recurrent/refractory peripheral T-cell lymphomas. Immunosuppression post-allo-SCT consisted of mycophenolate mofetil (through day þ 30) and tacrolimus (taper starting day þ 60). Neutrophil engraftment was achieved on day þ 14 with full donor chimerism confirmed on day þ 26. EBV PCR was 1239 copies per mL of plasma immediately before allo-SCT, then subsequently undetectable on day þ 30 and has remained undetectable since ( Figure 1) .
The patient was enrolled on a clinical trial with the Center for Cell and Gene Therapy at Baylor College of Medicine investigating the efficacy of EBV-specific CTL immunotherapy in patients with type II latency EBV malignancies. CTLs targeting the iummunosubdominant EBV-associated latent membrane protein-2 (LMP2) Ag were derived from the sibling donor's PBSCs as we have previously described. 5 The patient received LMP2-specific CTL infusions on days þ 183 and þ 197 without experiencing greater than grade I toxicities. He did not experience GVHD before CTL infusions and had a mild eczematous skin rash post-CTL that resolved with topical steroids. He is currently 2 years post-allo-SCT and in sustained CR with negative TCR rearrangement studies and an undetectable EBV PCR.
PET/computed tomography was used to monitor for disease recurrence post-allo-SCT. The patient had unremarkable PET scans before allo-SCT and at days þ 60, þ 93, and þ 181 showing minimal levels of FDG activity based on maximum standardized uptake values (SUVs). However, FDG-PET after the EBV-CTL infusions was highly abnormal with a steep increase in SUV levels (11 in Waldeyer's tonsillar ring and 6 in an inguinal lymph node) on day þ 237 (Figure 2a) . With high suspicion of relapse, inguinal lymph node biopsy and tonsillectomy were performed. Pathology review of both specimens revealed reactive lymphoid tissue without evidence of lymphoma (Figure 2b) . TCR rearrangement studies were polyclonal. These findings suggest that the CTL infusions were associated with lymphoid tissue activation resulting in the false-positive FDG-PET scans. Subsequent scans showed gradual normalization. EBV þ HV-like T-cell lymphoma is a notoriously refractory disease with poor outcomes. This is the first report of sequential matched EBV þ sibling allo-SCT followed by consolidation therapy with donor-derived EBV-specific CTL immunotherapy for a patient with an EBV þ T-cell malignancy. The life-saving role of EBV þ allo-SCT in the setting of this rare chemotherapy-resistant disease validates the critical importance in this adaptive immunotherapeutic approach to cure. We demonstrate that combination of reduced-intensity conditioning followed by EBV þ allo-SCT with subsequent EBV-CTL infusion is feasible and well tolerated. Although it remains unknown whether the patient would have experienced a sustained CR with EBV þ allo-SCT alone, the strong evidence for the efficacy of EBV-CTL therapy in patients with type III latency EBV þ B-cell LPD offers compelling rationale for optimizing treatment options with this consolidated approach in type II latency EBV þ T-cell lymphomas. Furthermore, we report on the occurrence of false-positive FDG-PET after infusion of LMP2-CTLs with subsequent self-resolution. PET scans have been reported to appear abnormal secondary to lymph node activation. 7 It is plausible that our patient experienced significant lymphoid activation after infusion of LMP2-CTLs resulting in the abnormal PET images. The encouraging outcomes for this patient with an EBV þ T-cell malignancy, a disease that characteristically carries a dismal prognosis, offers hope that this immunotherapeutic approach may offer improved chances for long-term survival in this group of high-risk patients. The Childhood, Adolescent, Young Adult Lymphoma Cell Therapy Consortium is a new initiative aiming to provide targeted cell therapy for patients with EBV þ lymphoma and evaluate the efficacy of these novel cellular immunotherapies on a larger scale.
